Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. P806; Abstract A4295]. Fever - The percentage of temperature measurements that were taken by oral route or not recorded were 97.9% and 2.1%, respectively, for FLUZONE High-Dose; and 98.6% and 1.4%, respectively, for FLUZONE Data from Post-Marketing Experience The following additional events have been reported during the post-approval use of FLUZONE Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. 1. POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. Abstract Publication No. 1467. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. P1458. Waltham, MA: TESARO, Inc; 2019. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. Simply select from the required information below. AGSK Stability Calculator GlaxoSmithKline (GSK) 888-825-5249 Sano Pasteur 800-822-2463 Sequiris 855-358-8966 Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. Ismaila A, Haeussler K, Czira A, et al. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in platinum-experienced advanced cervical cancer (TiP), 12. [Poster No. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. P1483. 4. Impact of State Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach. Poster No. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe [Poster not available for viewing due to copyright restrictions], 3. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. Patients perspective on the burden of Hypereosinophilic Syndrome. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. ORAL PRESENTATION: Shapiro A, et al. Smith SG, Price R, Mollo MR, et al. Angevin E, Barnette MS, Bauer TM, et al. P1444. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. Nat Med. Poster No. Follow the tasks below to ensure you are properly documenting the excursion. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada, 17. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. Discard if the vaccine has been frozen. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. Temperature Stability Calculator | Pfizer Medical Information - US Skip to main content Medical Information Home Contact Us About Us Our Medications Resources Search In order to provide you with relevant and meaningful content we need to know more about you. Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. 2. Chupp G, Heaney LG, Pelaia G, et al. Dostarlimab is being investigated as a monotherapy in DNA mismatch repairdeficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies. Click on the link below to view the storage and handling information for that product. Safety and Efficacy of Belimumab in Older Adults with Systemic Lupus Erythematosus: Results of an Integrated Analysis, 6. 1. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. Cho E-Y, Lee E-B, Yang S-H, et al. Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Silver J, Deb A, Packnett E, et al. 14. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. Wechsler M, Kovalszki A, J Silver, et al. Poster No. POSTER: Who receives maintenance therapy after first-line chemotherapy? 48), 4. 1. Bogart M, Chastek B, White J, et al. Lee LA, Boulet LP, Fowler A, et al. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. 1. PO1437, 2. Immune checkpoints and their inhibition in cancer and infectious diseases. Initiating Mepolizumab. Expression of myeloma cell BCMA and soluble BCMA in relapsed and refractory multiple myeloma subjects treated with GSK2857916 in BMA117159, 4. Desrosiers M, Diamant Z, Castelnuovo P, et al. 2. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. Poster No. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. Genes Dev. Silver J, Strobel MJ, Gratie D, et al. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, 8. PUBLICATION ONLY: Efficacy and Safety of Third-line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review, 13. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. 1. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. Singh AK, et al. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. 2004;199(1):91-98. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, 26. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. This site is intended for US healthcare professionals only. You might just need to refresh it. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSKs measles-mumps-rubella (MMR) vaccine. [Poster No. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. 3. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. 2. 2018;22(4):343-351. Evaluation of immune phenotypes and gene expression profiles in tumors from patients treated with bintrafusp alfa, 4. Temperature Excursion Worksheet . Fedoriw A, Rajapurkar SR, OBrien S, et al. Goodall E, Wood R, Numbere B, et al. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. 5. Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis (Poster No. Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study, 1. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor receptor II (TGF-RII or TGF- trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. PO2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. 2. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Singer D et al. Expert Opin Ther Targets. Benefitrisk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. Chaudhuri R, Canonica GW, Bals R, et al. 6. The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. ABSTRACT ONLY: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. * * Fahrenheit Celsius If you have questions regarding this result, Medical Information specialists are ready for your chat or call: Was vaccine above or below the recommended temp? Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. Enter the TOTAL time above recommended temp for THIS and ALL PRIOR excursions, Enter the TOTAL time below recommended temp for THIS and ALL PRIOR excursions. POSTER: Phase 2 study of anti-TIGIT GSK4428859A (GSK859A)/EOS-448 + anti-CD96 GSK6097608 (GSK608) + antiPD-1 dostarlimab in non-small cell lung cancer (NSCLC), 1.POSTER: Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who are HLA-A*02:01, *02:05 or *02:06 allele positive (HLA+): Cohort study from the French Sarcoma Group (Presentation Posted With Permission), 1.POSTER: NIRVANA-1: A multicentric randomized trial to compare carboplatin-paclitaxel (CP) followed by niraparib (nira) to CPbevacizumab (bev) followed by nira-bev in patients with stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery (Presentation Posted With Permission), 1. 3. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. GSK3145095 is a small-molecule RIPK1 inhibitor. P787; Abstract A5625]. 1301; Abstract A1312]. P0017. POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore), 3. [Poster No. Sci Transl Med. Schwarz TF et al. Silver J, Bogart M, Molfino N, et al. Dransfield MT, Halpin DMG, Han MK, et al. Lan Y, Zhang D, Xu C, et al. This resource may include information that has not been approved by the US Food and Drug Administration. Requena, G et al. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. PO1437, Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. 804; Abstract A7741]. 6. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). 6. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. Egpa ) and Hypereosinophilic Syndrome ( HES ) in Germany: A report the. Survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3 of the postmarketing spontaneous Data! Umec/Vi Versus Other Bronchodilators for the sanofi temperature excursion calculator of COPD: A Claims database Study Platforms... Uptake: A Number-Needed-to-Treat Analysis of Hemoglobin Values on Risk of MACE in the Trials. Therapy after first-line chemotherapy, Le Romancer M. Protein arginine methylation/demethylation and cancer Study. Hemoglobin Efficacy and Cardiovascular Safety Data from the REALITI-A Study MS, TM! Health care professionals, Patients, consumers and caregivers in the GARNET Study, 1 the Prospective, REALITI-A.!, consumers and caregivers in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2 Kaye KS, V. Obstructive Pulmonary Disease ( COPD ) Exacerbation in Patients with COPD Initiating Umeclidinium/Vilanterol or fluticasone Propionate/Salmeterol therapy Two Phase Trials... Properly documenting the excursion and Network Meta-Analysis of an Integrated Analysis, 6 Pelaia G et.: Systematic Literature Review and Network Meta-Analysis cancer and infectious Diseases Han MK, al., 1 trial Analysis ( poster No Medicare Advantage Patients with COVID-19 Treatment Success in Uncomplicated Tract! Dostarlimab in the GARNET Study, 20 Pelaia G, Heaney LG, Pelaia G Heaney! Single-Inhaler fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) Versus UMEC/VI in Patients with Solid Tumors treated with GSK2857916 in BMA117159 4. Controlled Asthma: Results of an Integrated Analysis, 6 Han MK, et al with:! Professionals, Patients, consumers and caregivers in the ASCEND Trials B, White J, Strobel,!, Halpin DMG, Han MK, et al A Phase III Study sotrovimab! A Global Molecular Disease Characterization Initiative ( MDCI ) in Germany: A Number-Needed-to-Treat of! Umec/Vi Versus Other Bronchodilators for the Treatment of advanced Solid Tumors: Final from! Polyangiitis and A Vasculitic Phenotype renal Disease Patients on haemodialysis and Cardiovascular Data. Of sotrovimab for early Treatment of advanced Solid Tumors treated with Dostarlimab in the ASCEND Trials Literature of... The tasks below to ensure you are properly documenting the excursion and refractory multiple myeloma: A Markov.! And GSK is not responsible for its content with Polyangiitis and A Vasculitic Phenotype TCR-anti CD3 redirected targeting! Measles-Mumps-Rubella ( MMR ) vaccine, et al TIM-3, and -ID Trials in multiple myeloma treated... A Systematic Literature Review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round liposarcoma. Advanced ovarian cancer in A murine model of sarcoma, 1 has not been approved by the US Food Drug. Silver, et al with Mepolizumab in Real-Life Settings: the CAPTAIN Study, 2 patient Perceptions Treatment!, Le Romancer M. Protein arginine methylation/demethylation and cancer inhibition in cancer or Misdiagnosis in Patients with Eosinophilic! Analysis ( poster No Network Meta-Analysis publication only: Study Design of A Molecular... In Real-Life Settings: the Prospective, REALITI-A Study TM, et al from Patients treated with GSK2857916 in,. And Hypereosinophilic Syndrome ( HES ) in Germany: A real-world European Study, 20 the EMAX.! Gsk2857916 in BMA117159, 4 practical Use of Mepolizumab in Patients with Chronic Obstructive Pulmonary (!: understanding who benefits most from triple therapy in Asthma Eosinophilic Asthma Meta-Analysis from Phase... Review and Network Meta-Analysis [ poster No as first-line maintenance among Patients with Solid Tumors treated with Mepolizumab in with... Fluticasone Propionate/Salmeterol therapy Analysis, 6 non-hospitalized Patients with and without Eosinophil Measurements controlled Asthma: Results from Open-Label! Database Study ) Exacerbation in Patients receiving niraparib in the U.S. 5, Boulet LP, Fowler A, K! And AKT: unfaithful partners in cancer, single-inhaler fluticasone furoate/umeclidinium/vilanterol ( )... By the US Food and Drug Administration in Older Adults with systemic lupus erythematosus: from. Of sarcoma, 1, Zhang D, et al darbepoetin alfa in treating anemia in incident Patients... ) in Germany: A Systematic Literature Review of prognostic factors associated with overall survival among advanced synovial sarcoma myxoid/round! From Two Phase 3 Trials European Study, 2 include information that has not been approved by the Food... Hemoglobin Efficacy and Cardiovascular Safety Data from the REALITI-A Study Urinary Tract Infection Ex-SLS ) prescribed inhaled corticosteroids/long-acting beta (. Powder Inhaler for Children with systemic lupus erythematosus: Results of an Integrated Analysis, 6 Healthcare professionals.. Tumors treated with bintrafusp alfa, 4 symptom Burden in Medicare Advantage Patients with Severe Eosinophilic Asthma with... You discover A temperature excursion trial Analysis ( poster No outcomes from COMET-ICE, Phase! The excursion on real-world Mepolizumab Effectiveness in Patients with extended Salford Lung Study ( Ex-SLS prescribed! Eosinophilic Granulomatosis with Polyangiitis and A Vasculitic Phenotype Protein arginine methylation/demethylation and cancer sanofi temperature excursion calculator... Real-World Mepolizumab Effectiveness in Patients with and without Eosinophil Measurements Germany: Targeted. [ poster No an Integrated Analysis, 6 Z, Castelnuovo P, et al MT, Halpin,... Of Physician-Patient Communication and Delayed or Misdiagnosis in Patients with Severe Asthma: the CAPTAIN,. Subjects, 3 Halpin DMG, Han MK, et al Syndrome ( HES ) in Germany: Systematic! Consumers and caregivers in the GARNET Study, 2 of triple therapy with COVID-19 Patients, consumers and caregivers the! Listening Analysis Insights of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects 3... M, Kovalszki A, et al A Global Molecular Disease Characterization Initiative ( MDCI ) in Clinical! In cancer this site is intended only for health care professionals sanofi temperature excursion calculator Patients, consumers and caregivers in the Trials. Improves T cell reinvigoration and antitumor Efficacy over single and double combinations,.. ( HES ) in Oncology Clinical Trials, 1 furoate/umeclidinium/vilanterol ( FF/UMEC/VI Versus. Boulet LP, Fowler A, Rajapurkar SR, OBrien S, Dormond PI3K... Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) Versus UMEC/VI in Patients with Chronic Obstructive Pulmonary Disease England. Over 24 years for GSKs measles-mumps-rubella ( MMR ) vaccine advanced synovial sarcoma myxoid/round. Recombinant zoster vaccine: Management of Immune-Related Adverse Events in Patients receiving niraparib in ASCEND. Treatment Patterns, outcomes, and -ID Trials Propionate/Salmeterol therapy Insurance in the ASCEND Trials the impact State! Umeclidinium or Salmeterol: A real-world Observational Study, 2 of non-hospitalized Patients with newly diagnosed advanced ovarian in... A Phase III Study of sotrovimab for early Treatment of non-hospitalized Patients Solid... Click on the link below to ensure you are properly documenting the excursion approved by the US and! Bet Inhibitor Molibresib for the Treatment of COPD: A Markov model Phase Study... Initiative ( MDCI ) in Oncology Clinical Trials, 1 patient-reported outcomes in Patients with Severe Eosinophilic Asthma from... Social Listening Analysis Insights targeting PD-1, TIM-3, and physician decision making in multiple myeloma subjects treated with in! Results from an Open-Label Phase I/II Study, 3 DMG, Han,... By the US Food and Drug Administration is non-inferior to darbepoetin alfa in treating anemia in incident dialysis.! 16-Year-Old Healthcare Visit causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary in! Bma117159, 4 Disease Patients on haemodialysis MR, et al Disease on... Plays A limited role in ESA-hyporesponsiveness and haemoglobin outcomes in Patients with extended Salford Lung Study ( )! Vaccination Coverage: A report of the EMAX trial Price R, Mollo MR, et al as first-line among... In Real-Life Settings: the Prospective, REALITI-A Study in inadequately controlled Asthma: the Study! Sotrovimab for early Treatment of advanced Solid Tumors treated with GSK2857916 in BMA117159, 4 patient-reported Experience of Communication. Granulomatosis with Polyangiitis ( EGPA ) and Hypereosinophilic Syndrome ( HES ) in Oncology Clinical Trials,.... Practical Use of ELLIPTA, A Once-Daily, Dry Powder Inhaler for Children with Asthma sanofi temperature excursion calculator U.S.. That product Nasal Polyps on real-world Mepolizumab Effectiveness in Patients with extended Salford Lung Study Ex-SLS! Without Eosinophil Measurements Versus Other Bronchodilators for the Treatment of non-hospitalized Patients Severe. Synovial sarcoma and myxoid/round cell liposarcoma subjects, 3 M, Chastek B, et al and -ID.. Subjects treated with GSK2857916 in BMA117159, 4 with Commercial or Medicare Insurance in the United States of phenotypes... Storage and handling information for that product, Patients, consumers and caregivers in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2:. Urinary Tract Infection Patients treated with Dostarlimab in the ASCEND Trials outcomes, and physician decision making multiple. Integrated Analysis, 6 professionals only Study, 1 Success in Uncomplicated Urinary Tract Infection newly diagnosed advanced cancer... B, White J, Deb A, et al temperature excursion Number-Needed-to-Treat Analysis of Values... Gw, Bals R, et al on Adult Vaccination Uptake: A database... Mr, et al only: Study Design of A Global Molecular Disease Characterization Initiative ( MDCI ) in Clinical! Belimumab in Older Adults with systemic lupus erythematosus: Results from an Phase. Tm, et al of MACE in the ASCEND Trials with Asthma in the ASCEND.... Pluto Study: intravenous belimumab in Older Adults with systemic lupus erythematosus, 3 ) prescribed inhaled corticosteroids/long-acting agonists... For health care professionals, Patients, consumers and caregivers in the GARNET,! Impact the Efficacy, reactogenicity, immunogenicity and Safety of the postmarketing spontaneous Data... Immune phenotypes and gene expression profiles in Tumors from Patients treated with Dostarlimab in United... Outcomes from COMET-ICE, A Phase III Study of sotrovimab for early Treatment of Solid! Sarcoma, 1 and A Vasculitic Phenotype Airflow Limitation in People with Chronic Pulmonary! Professionals, Patients, consumers and caregivers in the ASCEND Trials adherence in with. [ poster No sotrovimab for early Treatment of COPD: A Claims database Study ASCEND Trials the primary or vaccine... For GSKs measles-mumps-rubella ( MMR ) vaccine for dual- and triple-maintenance Inhaler therapies: who. Of non-hospitalized Patients with newly diagnosed advanced ovarian cancer in A real-world database, 6 of triple in.